Articles

Biotech company Canterbury Scientific has partly completed a study that could result in earlier detection of pre-eclampsia in pregnancy.  The company is one year into a two-year research project partnering with Canterbury Health Laboratories and the University of Otago, Christchurch, working on a diagnostic test method to identify pre-eclampsia earlier in pregnancy.  Read the full [...]

Ground-breaking New Zealand research could lower the death toll of women hit by pre-eclampsia. Read the article online.

Canterbury Scientific has been named in Technology Investment Network (TIN)’s ranking of top performing technology companies.  

This year’s TIN100 report paints a rosy picture of our high-tech companies, with revenue passing $7 billion, writes Rob O’Neill. “Biotechnology remains a small proportion, 5%, of TIN100 revenue, but even here there were strong performances from companies such as Argenta, AFT Pharmaceuticals, Pharmazen, and Canterbury Scientific. The top-10 emerging companies by growth recorded revenue [...]

Southern tech company growing fast Chris Hutching writes: “Christchurch-based biotechnology company, Canterbury Scientific, is one of the fastest growing companies in New Zealand.  The company has grown its revenue by 56% to $4.2 million. It is ranked 165 on the list and tipped as one of the top 10 Hot Emerging Companies of 2011.” New [...]

In New Zealand, many drivers of progressive technology have decades of experience behind them, reports Adam Gifford You can read the article online at the NZ Herald website.

Some of New Zealand’s fastest-growing and innovative companies would not have been successful without the help of the global financial crisis, according to the Technology Investment Network. You can also read the full article online at the NZ Herald website.

Canterbury Scientific Limited opened the doors to its new $1.2 million laboratory complex in Addington a few days before February’s devastating earthquake. The biotechnology company specialises in the development and production of quality controls for hematology and clinical biochemistry and boasts some of the world’s top medical companies as customers.  Read more

A collaboration is developing a potential biomarker for high blood pressure, which may be used for pre-eclampsia in the future.  Download the interview